ClinicalTrials.gg
CompletedNCT02853929Updated Jan 14, 2020Results posted

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

A Phase 4 interventional study of Infanrix hexa in Diphtheria, Hepatitis B and Acellular Pertussis, sponsored by GlaxoSmithKline. Completed at 29 sites in 6 countries. Open to participants aged 9 Months to 19 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-14.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
551
Allocation
Non-randomized
Ages
9 Months to 19 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Diphtheria.

Enrollment
6th of 15
551 · median 494
Started
2016
with 1 other
Phase 4
6 of 15
none open now
Registered
14th of 15
by date
Lead sponsor
14 of 15
GlaxoSmithKline

Among the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 4, and was the 14th registered.

Diphtheria

268 studies on the registry are indexed under Diphtheria; 18 are open to participants now.

Browse Diphtheria studies →

Open to participants now

None of the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria is open now. The open studies under Diphtheria, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 11 Diphtheria studies recruiting now, 2 (18%) set no upper age limit and 9 (82%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 9 Months to 19 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Diphtheria as a file.
02

Study summary

The purpose of this study is to assess the immunogenicity and safety of the Infanrix hexa booster dose given at 11-18 months of age to infants who received primary vaccination at 6-14 weeks. All infants in this booster study were born to pregnant women who participated in the study 116945 [DTPA (BOOSTRIX)-047] and having received the full primary vaccination series as per protocol requirement in study 201330 [DTPA (BOOSTRIX)-048.

03

Conditions studied

  • Diphtheria
  • Hepatitis B
  • Acellular Pertussis
  • Haemophilus Influenzae Type b
  • Tetanus
  • Poliomyelitis
  • Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Keywords

  • Pertussis
  • Immunogenicity
  • Poliomyelitis
  • Tetanus
  • Hepatitis B
  • Diptheria
04

Who can participate

Ages eligible
9 Months to 19 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects' parent(s)/Legally acceptable representatives (LAR(s)) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits).
  • Written obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
  • A male or female child 9 months of age at the time of enrolment.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Subjects born to mothers who were vaccinated in 116945 [DTPA (BOOSTRIX)-047] study and having completed their primary vaccination series as per protocol requirement in study 201330 [DTPA (BOOSTRIX)-048 PRI].

Exclusion criteria

Exclusion Criteria:

  • Child in care
  • Concurrently participating in another clinical study, within three months prior to the booster vaccine dose and at any time during the present booster study, in which the subject has been or will be exposed to an or a non-investigational vaccine/product (pharmaceutical product or device).
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs during the period within six months prior to the booster vaccine dose. For , this will mean prednisone ≥0.5mg/kg/day, or equivalent. Inhaled and topical steroids are allowed.
  • Administration of long-acting immune-modifying drugs at any time during the study period (e.g. infliximab).
  • A vaccine not foreseen by the study protocol administered during the period starting from 30 days before the booster dose of study vaccine and ending 30 days after*, with the exception of inactivated influenza vaccine and other vaccines given as a part of the national/regional immunization schedule, that are allowed at any time during the study period.

    • In case an emergency mass vaccination for an unforeseen public health threat (e.g.: a pandemic) is organised by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is licensed and used according to its SPC or Product Information (PI) and according to the local governmental recommendations and provided a written approval of the Sponsor is obtained.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
  • Major congenital defects.
  • Serious chronic illness.
  • Administration of immunoglobulins and/or any blood products during the period within three months before the booster dose of study vaccines or planned administration during the study period.
  • Encephalopathy defined as an acute, severe central nervous system disorder occurring within 7 days following vaccination with Infanrix hexa and generally consisting of major alterations in consciousness, unresponsiveness, generalised or focal seizures that persist more than a few hours, with failure to recover within 24 hours.
  • History of Hib, diphtheria, tetanus, pertussis, pneumococcal, poliovirus and diseases since the conclusion visit of study 201330 [DTPA (BOOSTRIX)-048 PRI].
  • Previous booster vaccination against Hib, diphtheria, tetanus, pertussis, pneumococcus, hepatitis B and/or poliovirus since the conclusion visit of study 201330 [DTPA (BOOSTRIX)-048 PRI].
  • History of any reaction or likely to be exacerbated by any component of the vaccines (e.g: antigen, ).
  • Hypersensitivity to latex.
  • History of any neurological disorders or seizures.
  • Any condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Acute disease and/or fever at the time of vaccination.

    • Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C /100.4°F on rectal route.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may be enrolled at the discretion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
551 participants (actual)

Study arms

  • Experimental
    dTpa Group

    This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a single dose of Boostrix during pregnancy and a dose of placebo immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure

    Biological: Infanrix hexa

  • Active comparator
    Control Group

    This group will consist of healthy male or female infants, aged 9 months at the time of enrollment, born to mothers who received a dose of placebo during pregnancy and single dose of Boostrix immediately post-delivery. All enrolled subjects in this group who will come back for subsequent visit will receive a booster dose of Infanrix hexa co-administered with Prevenar 13 according to the routine national/local immunization or study procedure

    Biological: Infanrix hexa

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D), Anti-tetanus (Anti-T), Anti-hepatitis B (Anti-HBs), Anti-poliovirus Type 1, Anti-poliovirus Type 2, Anti-poliovirus Type 3 and Anti-polyribosyl-ribitol Phosphate (Anti-PRP)

    Seroprotected subjects were defined as subjects with antibody concentrations/titres above or equal (≥) the assay cut-offs that are accepted immunological correlates of protection. 0.1 International units per milliliter (IU/ml) for anti-D and anti-T, 10 milli-International units per milliliter (mIU/mL) for anti-HB's, 8 Effective Dose 50 (ED50) for anti-polio virus (type 1,2,3) and 0.15 microgram/milliliter (µg/mL) for anti-PRP were considered as immunological correlates of protection.

    Time frame: At one month after the booster dose (Day 30)

  2. Number of Subjects With a Booster Response to Pertussis Antigens (Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN))

    Booster response to PT, FHA and PRN antigens was defined as: * for subjects with pre-vaccination antibody concentration below the assay cut-off, post-vaccination antibody concentration ≥ 4 times the assay cut-off, * for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off, post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and * for subjects with pre-vaccination antibody concentration ≥ 4 times the assay cut-off, post-vaccination antibody concentration ≥ 2 times the pre-vaccination antibody concentration Seronegative (S-) subjects are those who have antibody concentration less than (\<) assay cut-off. Seropositive (S+) subjects are those who have antibody concentration ≥ assay cut-off prior to vaccination. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti- FHA and 2.187 IU/mL for anti-PRN

    Time frame: At one month after the booster dose (Day 30)

Secondary outcomes

  1. Number of Seroprotected Subjects Against Anti-diphtheria, Anti-tetanus, Anti-poliovirus Type 1, Anti-poliovirus Type 2, Anti-poliovirus Type 3, Anti-HBs and Anti-PRP.

    Seroprotected subjects were defined as subjects with antibody concentrations/titers above or equal (≥) the assay cut-offs that are accepted immunological correlates of protection. 0.1 IU/mL for anti-D and anti-T, 10 mIU/mL for anti-HB's, 8 ED50 for anti-polio virus (type 1,2,3) and 0.15 µg/mL for anti-PRP were considered as immunological correlates of protection.

    Time frame: Before the booster dose (Day 0)

  2. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

    Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN

    Time frame: Before the booster dose (Day 0)

  3. Number of Seropositive Subjects for Anti-pneumococcal Serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)

    Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off's for anti-pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) are 0.080 µg/mL, 0.075 µg/mL, 0.061 µg/mL, 0.198 µg/mL, 0.111 µg/mL, 0.102 µg/mL, 0.063 µg/mL, 0.66 µg/mL, 0.160 µg/mL, 0.111 µg/mL, 0.199 µg/mL, 0.163 µg/mL, 0.073 µg/mL respectively.

    Time frame: Before the booster dose (Day 0)

  4. Anti-D, Anti-T, Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations

    Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in IU/mL.

    Time frame: Before the booster dose (Day 0) and One month after the booster dose (Day 30)

  5. Anti-poliovirus Type 1, 2, 3 Antibody Titres

    Anti-Poliovirus type 1, 2 and 3 antibody titers were expressed as Geometric Mean Titers (GMT).

    Time frame: Before the booster dose (Day 0) and One month after the booster dose (Day 30)

  6. Anti-HBs Antibody Concentrations

    Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in mIU/mL.

    Time frame: Before the booster dose (Day 0) and One month after the booster dose (Day 30)

  7. Anti-pneumococcal Serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and Anti-PRP Antibody Concentrations

    Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in µg/mL.

    Time frame: Before the booster dose (Day 0) and One month after the booster dose (Day 30)

  8. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.

    Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti- FHA and 2.187 IU/mL for anti-PRN

    Time frame: At one month after the booster dose (Day 30)

  9. Number of Subjects With Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness, swelling. Any redness, swelling is defined as a symptom with a surface diameter greater than 0 millimeter

    Time frame: During the 4-day (Day 0-Day 3) follow-up period after booster vaccination of two vaccines (Infanrix hexa and Prevenar 13)

  10. Number of Subjects With Solicited General Symptoms

    Assessed solicited general symptoms were Drowsiness, Fever, Irritability/Fussiness and Loss of appetite. Fever was defined as temperature ≥37.5 degree Celsius (°C) /99.5 degree Fahrenheit (°F) for oral, axillary or tympanic route, or ≥38.0°C/100.4°F on rectal route.

    Time frame: During the 4-day (Day 0-Day 3) follow-up period after booster vaccination

  11. Number of Subjects With Unsolicited Adverse Events (AEs)

    An AE was any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: During the 31-day (Day 0-Day 30) follow-up period after booster vaccination

  12. Number of Subjects With Serious Adverse Events (SAEs)

    SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, resulting in disability/incapacity

    Time frame: From booster dose up to study end (approximately 6 or 7 months, per subject)

  13. Number of Subjects With an ASQ-3 Score (Ages & Stages Questionnaires, Third Edition) in the Black Zone

    Neurodevelopmental status was measured by ASQ-3 score scale \[ASQ-3, 2016\] in the black zone. The ASQ-3 included a series of questions designed to assess 5 areas of development (communication, gross motor, fine motor, problem solving, and personal-social). Any subject who scored below the cut-off i.e., a score more than 2 Standard Deviations (SDs) below the mean score for the U.S. reference group (i.e., black zone in the score chart) in any of the 5 domains of the ASQ-3 was to be referred to a developmental specialist for a formal neurodevelopmental assessment (using the Bayley Scale for Infant Development, Version III \[BSID-III\])

    Time frame: At 9 months of age, 18 months of age, and 9 or 18 months of age

  14. Number of Subjects Referred for Formal Neurodevelopmental Evaluation Using BSID-III (Bayley Scale for Infant Development, Version III)

    Any subject who scored below the cut-off i.e., a score more than 2 Standard Deviations (SDs) below the mean score for the U.S. reference group (i.e., black zone in the score chart) in any of the 5 domains of the ASQ-3 was referred to a developmental specialist for a formal neurodevelopmental assessment (using the Bayley Scale for Infant Development, Version III BSID-III)

    Time frame: At 9 months of age, 18 months of age, and 9 or 18 months of age

  15. Estimated Proportion of Infants With at Least One of the Indicators of Neurodevelopmental Impairment Using BSID-III (Bayley Scale for Infant Development, Version III)

    The estimated proportion (expressed in percentage) of infants with a BSID-III indicator of neurodevelopmental delay was based on ASQ-3 black zone indicator and subsequent BSID-III assessment using the following formula: 100 \* (Number of subjects with ASQ-3 below cut off / Number of enrolled subjects with available results) \* (Number of subjects with at least one indicator of neurodevelopmental delay using BSID III / Number of subjects referred for BSID III evaluation)

    Time frame: At 9 months of age, 18 months of age, and 9 or 18 months of age

07

Results

Posted Jan 14, 2020

Participant flow

Subjects enrolled in the study were infants aged 9 months at the time of enrollment, born to mothers vaccinated with Boostrix in study 116945 BOOSTRIX-047 \[NCT02377349\] and who received primary vaccination Infanrix hexa co-administered with Prevenar 13 in study 201330 BOOSTRIX-048 \[NCT0242264\]

Participant flow — Overall Study
MilestonedTpa GroupControl Group
Started270281
Vaccinated263277
Completed259277
Not completed114
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject10
Withdrew: Subjects enrolled but not vaccinated74

Outcome measures

PrimaryNumber of Seroprotected Subjects Against Anti-diphtheria (Anti-D), Anti-tetanus (Anti-T), Anti-hepatitis B (Anti-HBs), Anti-poliovirus Type 1, Anti-poliovirus Type 2, Anti-poliovirus Type 3 and Anti-polyribosyl-ribitol Phosphate (Anti-PRP)

Seroprotected subjects were defined as subjects with antibody concentrations/titres above or equal (≥) the assay cut-offs that are accepted immunological correlates of protection. 0.1 International units per milliliter (IU/ml) for anti-D and anti-T, 10 milli-International units per milliliter (mIU/mL) for anti-HB's, 8 Effective Dose 50 (ED50) for anti-polio virus (type 1,2,3) and 0.15 microgram/milliliter (µg/mL) for anti-PRP were considered as immunological correlates of protection.

Time frame:
At one month after the booster dose (Day 30)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D), Anti-tetanus (Anti-T), Anti-hepatitis B (Anti-HBs), Anti-poliovirus Type 1, Anti-poliovirus Type 2, Anti-poliovirus Type 3 and Anti-polyribosyl-ribitol Phosphate (Anti-PRP)
ParticipantsdTpa GroupControl Group
Anti-D221247
Anti-T221247
Anti-HBs215239
Anti-polio 1204228
Anti-polio 2201227
Anti-polio 3188210
Anti-PRP221246
PrimaryNumber of Subjects With a Booster Response to Pertussis Antigens (Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN))

Booster response to PT, FHA and PRN antigens was defined as: * for subjects with pre-vaccination antibody concentration below the assay cut-off, post-vaccination antibody concentration ≥ 4 times the assay cut-off, * for subjects with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off, post-vaccination antibody concentration ≥ 4 times the pre-vaccination antibody concentration, and * for subjects with pre-vaccination antibody concentration ≥ 4 times the assay cut-off, post-vaccination antibody concentration ≥ 2 times the pre-vaccination antibody concentration Seronegative (S-) subjects are those who have antibody concentration less than (\<) assay cut-off. Seropositive (S+) subjects are those who have antibody concentration ≥ assay cut-off prior to vaccination. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti- FHA and 2.187 IU/mL for anti-PRN

Time frame:
At one month after the booster dose (Day 30)
Reported as:
Count of participants · Participants
Number of Subjects With a Booster Response to Pertussis Antigens (Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN))
ParticipantsdTpa GroupControl Group
Anti-PT, S-6240
Anti-PT, S+ (< 4*assay cut-off)98124
Anti-PT, S+ (≥ 4*assay cut-off)3871
Anti-PT, Overall198235
Anti-FHA, S-83
Anti-FHA, S+ (< 4*assay cut-off)8358
Anti-FHA, S+ (≥ 4*assay cut-off)117172
Anti-FHA, Overall208233
Anti-PRN, S-3431
Anti-PRN, S+ (< 4*assay cut-off)9076
Anti-PRN, S+ (≥ 4*assay cut-off)86133
Anti-PRN, Overall210240
SecondaryNumber of Seroprotected Subjects Against Anti-diphtheria, Anti-tetanus, Anti-poliovirus Type 1, Anti-poliovirus Type 2, Anti-poliovirus Type 3, Anti-HBs and Anti-PRP.

Seroprotected subjects were defined as subjects with antibody concentrations/titers above or equal (≥) the assay cut-offs that are accepted immunological correlates of protection. 0.1 IU/mL for anti-D and anti-T, 10 mIU/mL for anti-HB's, 8 ED50 for anti-polio virus (type 1,2,3) and 0.15 µg/mL for anti-PRP were considered as immunological correlates of protection.

Time frame:
Before the booster dose (Day 0)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Anti-diphtheria, Anti-tetanus, Anti-poliovirus Type 1, Anti-poliovirus Type 2, Anti-poliovirus Type 3, Anti-HBs and Anti-PRP.
ParticipantsdTpa GroupControl Group
Anti-D181220
Anti-T215232
Anti-HBs206229
Anti-polio 1188212
Anti-polio 2188215
Anti-polio 3188215
Anti-PRP161166
SecondaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN

Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti-FHA and 2.187 IU/mL for anti-PRN

Time frame:
Before the booster dose (Day 0)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
ParticipantsdTpa GroupControl Group
Anti-PT153201
Anti-FHA215241
Anti-PRN187213
SecondaryNumber of Seropositive Subjects for Anti-pneumococcal Serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)

Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off's for anti-pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) are 0.080 µg/mL, 0.075 µg/mL, 0.061 µg/mL, 0.198 µg/mL, 0.111 µg/mL, 0.102 µg/mL, 0.063 µg/mL, 0.66 µg/mL, 0.160 µg/mL, 0.111 µg/mL, 0.199 µg/mL, 0.163 µg/mL, 0.073 µg/mL respectively.

Time frame:
Before the booster dose (Day 0)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-pneumococcal Serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
ParticipantsdTpa GroupControl Group
Anti-pneumococcal serotype 1196214
Anti-pneumococcal serotype 3122147
Anti-pneumococcal serotype 4189215
Anti-pneumococcal serotype 5163182
Anti-pneumococcal serotype 6A196219
Anti-pneumococcal serotype 6B175205
Anti-pneumococcal serotype 7F210232
Anti-pneumococcal serotype 9V203225
Anti-pneumococcal serotype 14201223
Anti-pneumococcal serotype 18C168190
Anti-pneumococcal serotype 19A148172
Anti-pneumococcal serotype 19F183202
Anti-pneumococcal serotype 23F160191
SecondaryAnti-D, Anti-T, Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations

Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in IU/mL.

Time frame:
Before the booster dose (Day 0) and One month after the booster dose (Day 30)
Reported as:
Geometric mean · IU/ml
Anti-D, Anti-T, Anti-PT, Anti-FHA, Anti-PRN Antibody Concentrations
IU/mldTpa GroupControl Group
Anti-D at Day 00.207 (0.184 to 0.234)0.322 (0.285 to 0.363)
Anti-D at Day 306.114 (5.577 to 6.703)8.402 (7.694 to 9.174)
Anti-T at Day 00.753 (0.646 to 0.878)0.578 (0.506 to 0.659)
Anti-T at Day 308.200 (7.324 to 9.180)6.758 (6.143 to 7.433)
Anti-PT at Day 04.4 (3.8 to 5.0)6.3 (5.5 to 7.1)
Anti-PT at Day 3052.4 (46.9 to 58.4)80.3 (73.3 to 88.1)
Anti-FHA at Day 011.2 (9.6 to 13.1)16.5 (14.4 to 18.8)
Anti-FHA at Day 30152.5 (136.3 to 170.6)187.2 (172.7 to 202.9)
Anti-PRN at Day 06.9 (5.8 to 8.2)9.6 (8.3 to 11.2)
Anti-PRN at Day 30333.9 (285.4 to 390.7)262.3 (230.9 to 298.1)
SecondaryAnti-poliovirus Type 1, 2, 3 Antibody Titres

Anti-Poliovirus type 1, 2 and 3 antibody titers were expressed as Geometric Mean Titers (GMT).

Time frame:
Before the booster dose (Day 0) and One month after the booster dose (Day 30)
Reported as:
Geometric mean · Titers
Anti-poliovirus Type 1, 2, 3 Antibody Titres
TitersdTpa GroupControl Group
Anti-polio 1 at Day 064.9 (52.0 to 80.9)83.3 (67.7 to 102.5)
Anti-polio 1 at Day 301611.7 (1381.2 to 1880.6)1532.1 (1322.2 to 1775.3)
Anti-polio 2 at Day 071.7 (57.6 to 89.4)79.2 (64.4 to 97.5)
Anti-polio 2 at Day 302232.4 (1931.2 to 2580.5)2371.2 (2097.9 to 2680.1)
Anti-polio 3 at Day 0106.0 (84.1 to 133.4)118.4 (97.0 to 144.5)
Anti-polio 3 at Day 302944.6 (2529.4 to 3427.9)2891.8 (2496.2 to 3350.2)
SecondaryAnti-HBs Antibody Concentrations

Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in mIU/mL.

Time frame:
Before the booster dose (Day 0) and One month after the booster dose (Day 30)
Reported as:
Geometric mean · mIU/mL
Anti-HBs Antibody Concentrations
mIU/mLdTpa GroupControl Group
Anti-HBs at Day 0158.7 (129.9 to 194.0)193.4 (158.4 to 236.1)
Anti-HBs at Day 304858.3 (3918.4 to 6023.7)5031.2 (4072.7 to 6215.4)
SecondaryAnti-pneumococcal Serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and Anti-PRP Antibody Concentrations

Antibody concentrations are presented as Geometric Mean Concentrations (GMCs) and expressed in µg/mL.

Time frame:
Before the booster dose (Day 0) and One month after the booster dose (Day 30)
Reported as:
Geometric mean · µg/mL
Anti-pneumococcal Serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) and Anti-PRP Antibody Concentrations
µg/mLdTpa GroupControl Group
Anti-PnPS 1 at Day 00.22 (0.19 to 0.24)0.27 (0.24 to 0.30)
Anti-PnPS 1 at Day 303.22 (2.88 to 3.60)3.64 (3.28 to 4.04)
Anti-PnPS 3 at Day 00.08 (0.07 to 0.09)0.10 (0.09 to 0.11)
Anti-PnPS 3 at Day 300.59 (0.53 to 0.65)0.62 (0.57 to 0.69)
Anti-PnPS 4 at Day 00.15 (0.13 to 0.16)0.19 (0.17 to 0.22)
Anti-PnPS 4 at Day 302.91 (2.54 to 3.33)3.28 (2.89 to 3.72)
Anti-PnPS 5 at Day 00.33 (0.29 to 0.37)0.34 (0.31 to 0.38)
Anti-PnPS 5 at Day 302.66 (2.39 to 2.97)2.81 (2.52 to 3.14)
Anti-PnPS 6A at Day 00.38 (0.33 to 0.43)0.44 (0.39 to 0.50)
Anti-PnPS 6A at Day 309.07 (8.05 to 10.22)9.49 (8.45 to 10.67)
Anti-PnPS 6B at Day 00.29 (0.25 to 0.33)0.33 (0.29 to 0.38)
Anti-PnPS 6B at Day 307.83 (6.82 to 8.98)8.00 (7.06 to 9.06)
Anti-PnPS 7F at Day 00.49 (0.44 to 0.54)0.56 (0.51 to 0.61)
Anti-PnPS 7F at Day 305.00 (4.55 to 5.50)4.96 (4.50 to 5.48)
Anti-PnPS 9V at Day 00.26 (0.23 to 0.29)0.32 (0.28 to 0.36)
Anti-PnPS 9V at Day 303.74 (3.35 to 4.16)3.91 (3.52 to 4.35)
Anti-PnPS 14 at Day 00.97 (0.85 to 1.11)1.19 (1.04 to 1.37)
Anti-PnPS 14 at Day 3010.36 (9.22 to 11.64)11.62 (10.34 to 13.06)
Anti-PnPS 18C at Day 00.19 (0.17 to 0.21)0.23 (0.21 to 0.26)
Anti-PnPS 18C at Day 303.23 (2.86 to 3.65)3.57 (3.21 to 3.98)
Anti-PnPS 19A at Day 00.32 (0.27 to 0.37)0.37 (0.32 to 0.43)
Anti-PnPS 19A at Day 307.90 (7.06 to 8.83)8.68 (7.82 to 9.63)
Anti-PnPS 19F at Day 00.37 (0.32 to 0.43)0.47 (0.41 to 0.55)
Anti-PnPS 19F at Day 307.66 (6.84 to 8.57)8.63 (7.75 to 9.62)
Anti-PnPS 23F at Day 00.14 (0.12 to 0.16)0.19 (0.16 to 0.22)
Anti-PnPS 23F at Day 302.07 (1.83 to 2.34)2.38 (2.10 to 2.69)
Anti-PRP at Day 00.371 (0.303 to 0.453)0.292 (0.244 to 0.349)
Anti-PRP at Day 3026.186 (22.610 to 30.327)19.714 (16.891 to 23.010)
SecondaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.

Seropositive subjects were defined as subjects whose antibody concentration/titre was greater than or equal to the assay cut-off. Assay cut-off was 2.693 IU/mL for anti-PT, 2.046 IU/mL for anti- FHA and 2.187 IU/mL for anti-PRN

Time frame:
At one month after the booster dose (Day 30)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN.
ParticipantsdTpa GroupControl Group
Anti-PT220247
Anti-FHA221247
Anti-PRN220247
SecondaryNumber of Subjects With Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness, swelling. Any redness, swelling is defined as a symptom with a surface diameter greater than 0 millimeter

Time frame:
During the 4-day (Day 0-Day 3) follow-up period after booster vaccination of two vaccines (Infanrix hexa and Prevenar 13)
Reported as:
Count of participants · Participants
Number of Subjects With Solicited Local Symptoms
ParticipantsdTpa GroupControl Group
Pain134154
Redness143169
Swelling119122
SecondaryNumber of Subjects With Solicited General Symptoms

Assessed solicited general symptoms were Drowsiness, Fever, Irritability/Fussiness and Loss of appetite. Fever was defined as temperature ≥37.5 degree Celsius (°C) /99.5 degree Fahrenheit (°F) for oral, axillary or tympanic route, or ≥38.0°C/100.4°F on rectal route.

Time frame:
During the 4-day (Day 0-Day 3) follow-up period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Solicited General Symptoms
ParticipantsdTpa GroupControl Group
Drowsiness128138
Irritability163188
Loss of Appetite104116
Fever7385
SecondaryNumber of Subjects With Unsolicited Adverse Events (AEs)

An AE was any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
During the 31-day (Day 0-Day 30) follow-up period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited Adverse Events (AEs)
ParticipantsdTpa GroupControl Group
Number of Subjects With Unsolicited Adverse Events (AEs)94111
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalisation or prolongation of existing hospitalisation, resulting in disability/incapacity

Time frame:
From booster dose up to study end (approximately 6 or 7 months, per subject)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsdTpa GroupControl Group
Number of Subjects With Serious Adverse Events (SAEs)03
SecondaryNumber of Subjects With an ASQ-3 Score (Ages & Stages Questionnaires, Third Edition) in the Black Zone

Neurodevelopmental status was measured by ASQ-3 score scale \[ASQ-3, 2016\] in the black zone. The ASQ-3 included a series of questions designed to assess 5 areas of development (communication, gross motor, fine motor, problem solving, and personal-social). Any subject who scored below the cut-off i.e., a score more than 2 Standard Deviations (SDs) below the mean score for the U.S. reference group (i.e., black zone in the score chart) in any of the 5 domains of the ASQ-3 was to be referred to a developmental specialist for a formal neurodevelopmental assessment (using the Bayley Scale for Infant Development, Version III \[BSID-III\])

Time frame:
At 9 months of age, 18 months of age, and 9 or 18 months of age
Reported as:
Count of participants · Participants
Number of Subjects With an ASQ-3 Score (Ages & Stages Questionnaires, Third Edition) in the Black Zone
ParticipantsdTpa GroupControl Group
Any domain at Month 92728
Communication at Month 913
Gross motor skills at Month 91419
Fine motor at Month 983
Problem solving at Month 976
Personal- Social at Month 922
Any domain at Month 1865
Communication at Month 1810
Gross motor skills at Month 1832
Fine motor at Month 1811
Problem solving at Month 1813
Personal- Social at Month 1800
Any domain at Month 9 or 183131
Communication at Month 9 or 1823
Gross motor skills at Month 9 or 181620
Fine motor at Month 9 or 1894
Problem solving at Month 9 or 1888
Personal- Social at Month 9 or 1822
SecondaryNumber of Subjects Referred for Formal Neurodevelopmental Evaluation Using BSID-III (Bayley Scale for Infant Development, Version III)

Any subject who scored below the cut-off i.e., a score more than 2 Standard Deviations (SDs) below the mean score for the U.S. reference group (i.e., black zone in the score chart) in any of the 5 domains of the ASQ-3 was referred to a developmental specialist for a formal neurodevelopmental assessment (using the Bayley Scale for Infant Development, Version III BSID-III)

Time frame:
At 9 months of age, 18 months of age, and 9 or 18 months of age
Reported as:
Count of participants · Participants
Number of Subjects Referred for Formal Neurodevelopmental Evaluation Using BSID-III (Bayley Scale for Infant Development, Version III)
ParticipantsdTpa GroupControl Group
Any Domain at Month 91614
Any Domain at Month 1863
Any Domain at Month 9 or 182017
SecondaryEstimated Proportion of Infants With at Least One of the Indicators of Neurodevelopmental Impairment Using BSID-III (Bayley Scale for Infant Development, Version III)

The estimated proportion (expressed in percentage) of infants with a BSID-III indicator of neurodevelopmental delay was based on ASQ-3 black zone indicator and subsequent BSID-III assessment using the following formula: 100 \* (Number of subjects with ASQ-3 below cut off / Number of enrolled subjects with available results) \* (Number of subjects with at least one indicator of neurodevelopmental delay using BSID III / Number of subjects referred for BSID III evaluation)

Time frame:
At 9 months of age, 18 months of age, and 9 or 18 months of age
Reported as:
Number · Percentage of Infants
Estimated Proportion of Infants With at Least One of the Indicators of Neurodevelopmental Impairment Using BSID-III (Bayley Scale for Infant Development, Version III)
Percentage of InfantsdTpa GroupControl Group
Any domain at Month 94.39 (2.1 to 8.0)5.69 (3.0 to 9.6)
Any domain at Month 181.17 (0.2 to 3.4)0.61 (0.1 to 2.8)
Any domain at Month 9 or 184.61 (2.3 to 8.2)5.84 (3.2 to 9.7)

Adverse events

Collected over Solicited symptoms were collected during the 4-day (Day 0 - Day 3) follow-up period after each vaccination. Unsolicited AEs were collected during the 31-day (Day 0 - Day 30) follow-up period after each vaccination. SAEs were collected from booster dose up to study end (approximately 6 or 7 months, per subject). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
dTpa Group0/263 (0%)0/263 (0%)232/263 (88.2%)
Control Group0/277 (0%)3/277 (1.1%)257/277 (92.8%)
Most frequent serious events
Most frequent serious events
EventdTpa GroupControl Group
Periorbital cellulitisInfections and infestations0/2631/277
PneumoniaInfections and infestations0/2631/277
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders0/2631/277
Most frequent other events
Showing 10 of 99
Most frequent other events
EventdTpa GroupControl Group
IrritabilityPsychiatric disorders163/263189/277
Injection site erythemaGeneral disorders143/263169/277
Injection site painGeneral disorders134/263154/277
SomnolenceNervous system disorders128/263138/277
Injection site swellingGeneral disorders119/263122/277
Decreased appetiteMetabolism and nutrition disorders104/263116/277
PyrexiaGeneral disorders81/263101/277
NasopharyngitisInfections and infestations12/26310/277
Ear infectionInfections and infestations9/26312/277
VomitingGastrointestinal disorders10/2638/277

Baseline characteristics

Age, Customized
Age, Customized(Participants)dTpa GroupControl GroupTotal
Infants and toddlers (28 days-23 months)270281551
Sex: Female, Male
Sex: Female, Male(Participants)dTpa GroupControl GroupTotal
Female127128255
Male143153296
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)dTpa GroupControl GroupTotal
African Heritage / African American4913
Asian - East Asian Heritage101
Asian - South East Asian Heritage202
White - Arabic / North African Heritage134
White - Caucasian / European Heritage246262508
Other16723
08

Study locations

29 sites
  • GSK Investigational Site
    Carlton, Victoria 3053, Australia
  • GSK Investigational Site
    Calgary, Alberta T3B 6A8, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3K 6R8, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1C5, Canada
  • GSK Investigational Site
    Brno, 613 00, Czechia
  • GSK Investigational Site
    Hradec Kralove, 500 02, Czechia
  • GSK Investigational Site
    Ostrava - Vitkovice, 703 84, Czechia
  • GSK Investigational Site
    Praha 4, 140 59, Czechia
  • GSK Investigational Site
    Praha, 14700, Czechia
  • GSK Investigational Site
    Kokkola, 67100, Finland
  • GSK Investigational Site
    Oulu, 90220, Finland
  • GSK Investigational Site
    Seinajoki, 60100, Finland
  • GSK Investigational Site
    Tampere, 33100, Finland
  • GSK Investigational Site
    Turku, 20520, Finland
  • GSK Investigational Site
    Milano, Lombardia 20122, Italy
  • GSK Investigational Site
    Milano, Lombardia 20142, Italy
  • GSK Investigational Site
    Milano, Lombardia 20154, Italy
  • GSK Investigational Site
    Novara, Piemonte 28100, Italy
  • GSK Investigational Site
    Malaga, Andalucia 29004, Spain
  • GSK Investigational Site
    Antequera/Málaga, 29200, Spain
  • GSK Investigational Site
    Aravaca, 28023, Spain
  • GSK Investigational Site
    Burgos, 09006, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Madrid, 28050, Spain
  • GSK Investigational Site
    Majadahonda (Madrid), 28222, Spain
  • GSK Investigational Site
    Móstoles, 28938, Spain
  • GSK Investigational Site
    Santiago de Compostela, 15706, Spain
  • GSK Investigational Site
    Sevilla, 41014, Spain
09

References and documents

Publications

  • Martinon-Torres F, Halperin SA, Nolan T, Tapiero B, Perrett KP, de la Cueva IS, Garcia-Sicilia J, Stranak Z, Vanderkooi OG, Kosina P, Rumlarova S, Virta M, Arribas JMM, Miranda-Valdivieso M, Novas BA, Bozensky J, Ortega MJC, Amador JTR, Baca M, Palomino EE, Zuccotti GV, Janota J, Marchisio PG, Kostanyan L, Meyer N, Ceregido MA, Cheuvart B, Kuriyakose SO, Mesaros N. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial. Vaccine. 2021 Mar 12;39(11):1598-1608. doi: 10.1016/j.vaccine.2021.02.001. Epub 2021 Feb 19. PubMed 33612341 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Mar 2019, 30 months.

Results were first posted in Jan 2020, 9 months after primary completion.

Of 21 phase 4 interventional studies under Diphtheria, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2016
First posted
Aug 3, 2016
StartActual
Sep 19, 2016
Primary completionActual
Mar 19, 2019
CompletionActual
Mar 19, 2019
Results first posted
Jan 14, 2020
Last update
Jan 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02853929
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 3, 2016
Start date
Sep 19, 2016
Primary completion
Mar 19, 2019
Completion
Mar 19, 2019
Results posted
Jan 14, 2020
Last update
Jan 14, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion